FDA 483 - Ferring Pharmaceuticals Inc - March 14, 2023

An FDA inspection of Ferring Pharmaceuticals Inc. in Parsippany, NJ, identified a significant issue regarding the monitoring of clinical studies. The firm failed to ensure proper oversight of investigational product storage, specifically noting unreported temperature deviations. This indicates a lapse in critical study monitoring practices.